Industry
Biotechnology
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
February 27, 2024 | 8:02 pm
Portfolio Pulse from Happy Mohamed
December 18, 2023 | 2:49 pm
Portfolio Pulse from bharat@benzinga.com
November 08, 2023 | 10:19 pm
Portfolio Pulse from Benzinga Insights
November 07, 2023 | 6:01 pm
Portfolio Pulse from richadhand@benzinga.com
August 10, 2023 | 9:29 am
Portfolio Pulse from mahesh@benzinga.com
August 08, 2023 | 9:39 pm
Portfolio Pulse from Benzinga Insights
August 07, 2023 | 7:01 pm
Portfolio Pulse from Benzinga Newsdesk
June 15, 2023 | 11:04 am
Portfolio Pulse from Lisa Levin
May 30, 2023 | 5:27 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.